Study of Anti-5T4 CAR-NK Cell Therapy in Advanced Solid Tumors

• ClinicalTrials.gov Identifier: NCT05194709
• Recruitment Status: Recruiting
• First Posted: January 18, 2022
• Last Update Posted: February 2, 2022
• Sponsor: Wuxi People's Hospital
• Collaborator: Imbioray (Hangzhou) Biomedicine Co., Ltd.
• Information provided by (Responsible Party): Wuxi People's Hospital

Tracking Information

• First Submitted Date: January 4, 2022
• First Posted Date: January 18, 2022
• Last Update Posted Date: February 2, 2022
• Actual Study Start Date: December 30, 2021
• Estimated Primary Completion Date: December 30, 2022 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: January 14, 2022)

Number of Adverse Events (AEs) [ Time Frame: From day 1 to day 90 after the last dose ]

To evaluate the safety and tolerability of anti-5T4 CAR-NK cells

• Original Primary Outcome Measures: Same as current

Current Secondary Outcome Measures (submitted: January 14, 2022)

• Objective response rate (ORR) [ Time Frame: Up to 1 year after infusion ]
  To determine the anti-tumor effectivity of anti-5T4 CAR-NK cells
• Progression-free survival (PFS) [ Time Frame: Up to 1 year after infusion ]
  To determine the anti-tumor effectivity of anti-5T4 CAR-NK cells
• Overall survival (OS) [ Time Frame: Up to 1 year after infusion ]
  To determine the anti-tumor effectivity of anti-5T4 CAR-NK cells
• Disease control rate (DCR) [ Time Frame: Up to 1 year after infusion ]
  To determine the anti-tumor effectivity of anti-5T4 CAR-NK cells
• Cytokine release [ Time Frame: Up to 1 year ]
  Blood samples will be collected at specified time points to detect the cytokine (IL-1β, IL-2, IL-4, IL-6, IL-10, IFN-γ, hsCRP) concentration (pg/mL)
• Lymphocyte subtype [ Time Frame: Up to 1 year ]
  Blood samples will be collected at specified time points to analyze the lymphocyte subtypes (CD3, CD4, CD8, CD19, CD56)

• Original Secondary Outcome Measures: Same as current
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Study of Anti-5T4 CAR-NK Cell Therapy in Advanced Solid Tumors
• Official Title: Clinical Trial of Anti-5T4 Oncofetal Trophoblast Glycoprotein (5T4) Conjugated Antibody Redirecting Natural Killer (CAR-NK) Cells in Advanced Solid Tumors
• Brief Summary: This study is an interventional, single arm, open-label, investigator-initiated trial (IIT) to evaluate the safety, tolerability, initial efficacy and pharmacokinetics (PK) of anti-5T4 CAR-NK cells in patients with advanced solid tumors.
• Detailed Description: The treatment cycle in this study is 21 days. The administration of CAR-NK cell will be performed on day 1 and day 3 of each cycle. Subjects will be treated continuously until the criteria for termination of treatment are met. In this study, the dose escalation design is adopted. The first administration dose in the first cycle is 3.0×10^9 cells. If no adverse events were observed, the second administration dose in the first cycle would be 4.0×10^9 cells, and each administration dose in the second cycle and thereafter would be 4.0×10^9 cells.
• Study Type: Interventional
• Study Phase: Early Phase 1
• Study Design: Allocation: N/A; Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Treatment
• Condition: Advanced Solid Tumors

Intervention

Biological: Anti-CAR-NK Cells

The administration of CAR-NK cell will be performed on day 1 and day 3 of each cycle (21 days). The first administration dose in the first cycle is 3.0×10^9 cells. If no adverse events were observed, the second administration dose in the first cycle would be 4.0×10^9 cells, and each administration dose in the second cycle and thereafter would be 4.0×10^9 cells.

Study Arms

Experimental: Anti-5T4 CAR-NK Cells

Intervention: Biological: Anti-CAR-NK Cells

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Recruiting
• Estimated Enrollment (submitted: January 14, 2022): 40
• Original Estimated Enrollment: Same as current
• Estimated Study Completion Date: December 30, 2022
• Estimated Primary Completion Date: December 30, 2022 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

1. Subjects volunteer to participate in this clinical study, are fully aware of the study and have signed the Informed Consent Form (ICF). Subjects are willing to follow and able to complete all trial procedures.
2. Age: adult at the age of 18-80 (both inclusive), female or male.
3. Patients with advanced malignant solid tumors, histologically or cytologically confirmed, who had failed standard therapy, or had no standard therapy, or were not eligible for standard therapy at this stage; tumor biomarkers combined with imaging can be used to diagnose some special advanced tumors.
4. Eastern Cooperative Oncology Group (ECOG) score ≤2 and expected survival time >3 months.

5. Organ function during screening should meet the following criteria:

   • Absolute neutrophil count (ANC)≥0.8×109/L
   • Platelet (PLT)≥50×109/L
   • Hemoglobin (Hb)≥80g/L
   • Total bilirubin (TBIL)≤2×ULN
   • Alanine aminotransferase (ALT)≤3×ULN; Patients with liver metastasis or liver cancer: ≤5×ULN
   • Aspartate aminotransferase (AST)≤3×ULN; Patients with liver metastasis or liver cancer: ≤5×ULN
   • Creatinine (Cr)≤1.5× ULN
   • Creatinine clearance (Ccr) (to be calculated only when Cr > 1.5× ULN)>50ml/min/1.73m2 (Cockcroft-Gault formula)
   • Activated partial thrombin time (APTT)≤1.5×ULN
   • International normalized ratio (INR)≤1.5×ULN
6. Subjects of reproductive age and their partners should agree to have no family planning and to use effective contraceptive methods (hormonal or barrier methods or abstinence, etc.) for 6 months from signing the ICF until the last dose of the study drug is administered; women of reproductive age should not be pregnant or breastfeeding.

Exclusion Criteria:

1. Have received systemic antitumor therapy, including chemotherapy, immunotherapy, and radical radiotherapy, within 1 week prior to their first use of the study drug.
2. Have participated in other clinical trials and received any unmarketed investigational drug or treatment within 4 weeks prior to first use of the study drug.
3. Any prior adoptive cellular immunotherapy.
4. Have undergone major organ surgery (excluding needle biopsy or surgery related to this indication) within 4 weeks prior to their first use of the study drug, or required elective surgery during the study period.
5. Patients with severe infections that cannot be controlled.
6. Patients with a known history of human immunodeficiency virus (HIV) infection, or a history of organ transplantation.
7. Have active autoimmune diseases or have had autoimmune diseases that are likely to recur (e.g., systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, autoimmune thyroid disease, vasculitis, psoriasis, etc.). Except in the following cases: type 1 diabetes that was well controlled with hormone replacement therapy, hypothyroidism, skin conditions that did not require systemic therapy (e.g., vitiligo), and other conditions that were well controlled and that the investigator determined were less likely to recur (e.g., childhood asthma in remission).

8. Have a history of serious cardiovascular and cerebrovascular diseases, including but not limited to:

   • There are serious cardiac rhythm or conduction abnormalities, such as ventricular arrhythmia, and Ⅱ-Ⅲ degree atrioventricular block, which need clinical intervention;
   • The mean QT interval corrected by Fridericia method (QTcF) is prolonged (male>450ms, female>470ms);
   • Acute coronary syndrome, congestive heart failure, aortic dissection, stroke, or other grade 3 or above cardiovascular and cerebrovascular events occurring within 6 months before the first administration;
   • Patients with heart failure or left ventricular ejection fraction (LVEF) < 50% in the New York Heart Association (NYHA) classification ≥II;
   • Hypertension beyond clinical control.
9. Adverse effects of previous antineoplastic therapy have not returned to CTCAE grade 5.0≤2 (except for toxicity that the investigator determined to be of no safety risk, such as alopecia, hypothyroidism stabilized by hormone replacement therapy).
10. Central nervous system metastases with clinical symptoms.
11. Had other malignant tumors in the past 3 years, excluding skin basal cell carcinoma, ductal carcinoma in situ and cervical carcinoma in situ with a radical surgery.
12. Have a history of alcohol or drug abuse or mental disorder.
13. The investigator considered that the subjects had a history of other serious systemic diseases or other reasons that made them unsuitable for the study.

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years to 80 Years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Contacts

Contact: Peihua Lu, MD; +8613583991399; lyzlyylxm@163.com

• Listed Location Countries: China

Administrative Information

• NCT Number: NCT05194709
• Other Study ID Numbers: IBR854-T01; WX-IBR-8 ( Other Identifier: Wuxi People's Hospital )
• Has Data Monitoring Committee: No

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

IPD Sharing Statement

• Plan to Share IPD: No

• Current Responsible Party: Wuxi People's Hospital
• Original Responsible Party: Same as current
• Current Study Sponsor: Wuxi People's Hospital
• Original Study Sponsor: Same as current
• Collaborators: Imbioray (Hangzhou) Biomedicine Co., Ltd.

Investigators

• Principal Investigator: Peihua P Lu, MD; Wuxi People's Hospital

• PRS Account: Wuxi People's Hospital
• Verification Date: January 2022